Hoffmann-La Roche Limited operates as a member of the Roche Group and has spent nearly fifty years discovering and developing medicines for serious and life-threatening diseases. The company was founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer, establishing what became a cornerstone of the modern biotechnology industry.
The company's technical capabilities span oncology, neuroscience, personalized medicine, and pharmaceutical manufacturing. Notable achievements include developing the first personalized medicine for cancer and the first medicine for primary progressive multiple sclerosis. Hoffmann-La Roche has invested in artificial intelligence for molecule discovery and maintains state-of-the-art manufacturing facilities in the United States, where it has committed $50 billion to manufacturing and research and development.
Current work encompasses clinical trials, biomedical research, and customer engagement strategies. The company has prioritised efforts to improve clinical trial participation and drive inclusive research aimed at optimising health outcomes across patient populations.
